Are statin trials in diabetes representative of real-world diabetes care: A population-based study on statin initiators in Finland

BMJ Open

Volumn 4, Issue 6, 2014, Pages

  Ruokoniemi, Päivi ^a   Sund, Reijo ^b   Arffman, Martti ^b   Helin Salmivaara, Arja ^a   Huupponen, Risto ^a,c   Keskimäki, Ilmo ^b,d   Vehko, Tuulikki ^b   Korhonen, Maarit Jaana ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; SIMVASTATIN; SULFONYLUREA;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; COMORBIDITY; DIABETES MELLITUS; FEMALE; FINLAND; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RISK FACTOR; STATISTICS; AGED; CLINICAL TRIAL (TOPIC); MIDDLE AGED; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS; FEMALE; FINLAND; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED;

EID: 84903178569     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005402     Document Type: Article

References (55)

1. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769-818.
2. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur J Prev Cardiol 2012;4:585-667.
3. National Institute for Health and Clinical Excellence. Type 2 diabetes: the management of type 2 diabetes (update) - clinical guidelines. 2008. http://www.nice.uk.com
4. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care 2013;36(Suppl 1):S11-66.
5. Finnish Medical Society Duodecim. Diabetes (online) Käypä Hoitosuositus. (In Finnish, summary in English: Diabetes. Current care guideline). Working group appointed by the Finnish Medical Society Duodecim, the Finnish Society of Internal Medicine and the Medical Advisory Board of the Finnish Diabetes Society. Helsinki, 2011. http://www.kaypahoito.fi
6. Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34. (Pubitemid 28350165)
7. Schramm TK, Gislason GH, Køber L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008;117:1945-54. (Pubitemid 351543470)
8. Dominguez H, Schramm TK, Norgaard ML, et al. Initiation and persistence to statin treatment in patients with diabetes receiving glucose-lowering medications 1997-2006. Open Cardiovasc Med J 2009;3:152-9.
9. Eliasson B, Svensson AM, Miftaraj M, et al. Clinical use and effectiveness of lipid lowering therapies in diabetes mellitus-an observational study from the Swedish National Diabetes Register. PLoS ONE 2011;6:e18744.
10. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
11. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
12. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96. (Pubitemid 39140624)
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
14. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
15. Atkins D, Chang S, Gartlehner G, et al. Assessing the Applicability of Studies When Comparing medical Interventions. Agency for Healthcare Research and Quality, January 2011. Methods Guide for Comparative Effectiveness Reviews. AHQR Publication No. 11-EHC019-EF. http://effectivehealthcare.ahrq.gov/ (accessed 6 May 2012).
16. Bartlett C, Doyal L, Ebrahim S, et al. The causes and effects of socio-demographic exclusions from clinical trials. Health Technol Assess 2005;9:iii-iv. ix-x, 1-152.
17. Konrat C, Boutron I, Trinquart L, et al. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS ONE 2012;7:e33559.
18. Bandyopadhyay S, Bayer AJ, O'Mahony MS. Age and gender bias in statin trials. QJM 2001;94:127-32. (Pubitemid 32242000)
19. Wei L, Ebrahim S, Bartlett C, et al. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005;330:821.
20. Sund R, Koski S. FinDM II. On the register-based measurement of the prevalence and incidence of diabetes and its long-term complications. A Technical Report. Tampere: The Finnish Diabetes Association, 2009.
21. Korhonen MJ, Helin-Salmivaara A, Huupponen R. Dynamics of long-term statin therapy. Eur J Clin Pharmacol 2011;67:925-31.
22. Winell KM, Pääkkönen R, Pietilä A, et al. Case fatality rates after first acute coronary syndrome in persons treated for type 2 diabetes show an improving trend. Diabetologia 2010;53:472-80.
23. Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish Hospital Discharge Register and Causes of Death Register data on coronary heart disease. Eur J Cardiovasc Prev Rehabil 2005;12:132-7. (Pubitemid 40575756)
24. Tolonen H, Salomaa V, Torppa J, et al. The validation of the Finnish Hospital Discharge Register and Causes of Death Register data on stroke diagnoses. Eur J Cardiovasc Prev Rehabil 2007;3:380-5. (Pubitemid 46945560)
25. Sund R. Quality of the Finnish Hospital Discharge Register: a systematic review. Scand J Public Health 2012;40:505-15.
26. Leslie RS, Gwadry-Sridhar F, Thiebaud P, et al. Calculating medication compliance, adherence and persistence in administrative pharmacy claims databases. Pharm Programming 2009;1:13-19.
27. Benner J, Glynn R, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61. (Pubitemid 34787476)
28. Perreault S, Dragomir A, Blais L, et al. Impact of better adherence to statin agents in the primary prevention of coronary artery disease. Eur J Clin Pharmacol 2009;65:1013-24.
29. US Food and Drug Administration: Relative LDL-lowering Efficacy of Statin and Statin-based Therapies. http://www.fda.gov (accessed in Jul 2012).
30. van Staa TP, Smeeth L, Ng ES, et al. The efficiency of cardiovascular risk assessment: do the right patients get statin treatment? Heart 2013;99:1597-602.
31. Rothwell PM. External validity of randomised controlled trials: 'to whom do the results of this trial apply?' Lancet 2005;365:82-93. (Pubitemid 40082150)
32. Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007;297:1233-40. (Pubitemid 46465731)
33. Britton A, McKee M, Black N, et al. Threats to applicability of randomised trials: exclusions and selective participation. J Health Serv Res Policy 1999;4:112-21. (Pubitemid 29186862)
34. Lee S, Monz BU, Clemens A, et al. Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open 2012;14, 2:pii:e001768.
35. Saunders C, Byrne CD, Guthrie B, et al. External validity of randomized controlled trials of glycemic control and vascular disease: how representative are participants? Diabet Med 2013;30:300-8.
36. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504. (Pubitemid 38477774)
37. Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20. (Pubitemid 27143424)
38. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation 1998;98:2513-19. (Pubitemid 29001188)
39. Knopp RH, d'Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006;29:1478-85. (Pubitemid 44127567)
40. Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151-7. (Pubitemid 40616627)
41. American Diabetes Association. Nutrition recommendations and interventions for diabetes - 2006. Diabetes Care 2006;29:2140-57.
42. American Association of Diabetes Educators. Position statement. intensive diabetes management: implications of the DCCT and UKPDS. Diabetes Educ 2002;28:735-40.
43. Kuusisto J, Laakso M. Update on type 2 diabetes as a cardiovascular disease risk equivalent. Curr Cardiol Rep 2013;15:331.
44. Charlton J, Latinovic R, Gulliford MC. Explaining the decline in early mortality in men and women with type 2 diabetes: a population-based cohort study. Diabetes Care 2008;9:1761-6.
45. Mann DM, Woodward M, Ye F, et al. Trends in medication use among US adults with diabetes mellitus: glycemic control at the expense of controlling cardiovascular risk factors. Arch Intern Med 2009;169:1718-20.
46. González EL, Johansson S, Wallander MA, et al. Trends in the prevalence and incidence of diabetes in the UK: 1996-2005. J Epidemiol Community Health 2009;63:332-6.
47. Vehko T, Manderbacka K, Arffman M, et al. Changing patterns of secondary preventive medication among newly diagnosed coronary heart disease patients with diabetes in Finland: a register-based study. Scand J Public Health 2010;38:317-24.
48. Gulliford MC, Charlton J. Is relative mortality of type 2 diabetes mellitus decreasing? Am J Epidemiol 2009;169:455-61.
49. Donnelly LA, Doney ASF, Morris AD, et al. Long-term adherence to statin treatment in diabetes. Diabet Med 2008;25:850-5.
50. Perreault S, Blais L, Lamarre D, et al. Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol 2005;59:564-73. (Pubitemid 40632247)
51. Sund R, Harno K, Ranta S, et al. Evaluation of case inclusion in two population-based diabetes registers. Fin J eH eW 2010;2:136-46.
52. Lesen E, Sandstrom TZ, Carlsten A, et al. A comparison of two methods for estimating refill adherence to statins in Sweden: the RARE project. Pharmacoepidemiol Drug Saf 2011;20:1073-9.
53. Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-87.
54. Kiivet R, Sund R, Linna M, et al. Methodological challenges in international performance measurement using patient-level administrative data. Health Policy 2013;112:110-21.
55. Stone MA, Charpentier G, Doggen K, et al. Quality of care of people with type 2 diabetes in eight European countries. Diabetes Care 2013;36:2628-38.